{
    "guideline": {
        "id": "PA166105006",
        "name": "Annotation of CPIC Guideline for amitriptyline and CYP2C19, CYP2D6",
        "source": "CPIC",
        "version": 58,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166105006",
        "relatedChemicals": [
            {
                "id": "PA448385",
                "name": "amitriptyline",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA124",
                "name": "cytochrome P450 family 2 subfamily C member 19",
                "symbol": "CYP2C19"
            },
            {
                "id": "PA128",
                "name": "cytochrome P450 family 2 subfamily D member 6",
                "symbol": "CYP2D6"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166297055",
            "name": "Recommendation PA166297055",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059657,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297152",
            "name": "Recommendation PA166297152",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059754,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297108",
            "name": "Recommendation PA166297108",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059710,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166296983",
            "name": "Recommendation PA166296983",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059585,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297187",
            "name": "Recommendation PA166297187",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059789,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "4.0",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297042",
            "name": "Recommendation PA166297042",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059644,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166296996",
            "name": "Recommendation PA166296996",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059598,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166301338",
            "name": "Recommendation Annotation PA166301338",
            "population": null,
            "classification": null,
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452095657,
                "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x\u22653</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x\u22653</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x\u22653</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x\u22653</strong> or <strong>*2x2 versus *2x\u22653</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x\u22653</td>\n<td>Increased</td>\n<td>\u22653</td>\n<td></td>\n<td></td>\n<td>\u22653</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
            },
            "implications": [],
            "lookupKey": {
                "CYP2D6": "xN combinations",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297077",
            "name": "Recommendation PA166297077",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059679,
                "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297174",
            "name": "Recommendation PA166297174",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059776,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.25",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297064",
            "name": "Recommendation PA166297064",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059666,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297161",
            "name": "Recommendation PA166297161",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059763,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297156",
            "name": "Recommendation PA166297156",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059758,
                "html": "<p>Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297011",
            "name": "Recommendation PA166297011",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059613,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297059",
            "name": "Recommendation PA166297059",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059661,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166296987",
            "name": "Recommendation PA166296987",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059589,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297143",
            "name": "Recommendation PA166297143",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059745,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297090",
            "name": "Recommendation PA166297090",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059692,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297046",
            "name": "Recommendation PA166297046",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059648,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166301334",
            "name": "Recommendation Annotation PA166301334",
            "population": null,
            "classification": null,
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452095653,
                "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x\u22653</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x\u22653</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x\u22653</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x\u22653</strong> or <strong>*2x2 versus *2x\u22653</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x\u22653</td>\n<td>Increased</td>\n<td>\u22653</td>\n<td></td>\n<td></td>\n<td>\u22653</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
            },
            "implications": [],
            "lookupKey": {
                "CYP2D6": "xN combinations",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297178",
            "name": "Recommendation PA166297178",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059780,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.25",
                "CYP2C19": "No Result"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297033",
            "name": "Recommendation PA166297033",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059635,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297130",
            "name": "Recommendation PA166297130",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059732,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297165",
            "name": "Recommendation PA166297165",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059767,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297020",
            "name": "Recommendation PA166297020",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059622,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297068",
            "name": "Recommendation PA166297068",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059670,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297100",
            "name": "Recommendation PA166297100",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059702,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297095",
            "name": "Recommendation PA166297095",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059697,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297148",
            "name": "Recommendation PA166297148",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059750,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297192",
            "name": "Recommendation PA166297192",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059794,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297003",
            "name": "Recommendation PA166297003",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059605,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297082",
            "name": "Recommendation PA166297082",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059684,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297135",
            "name": "Recommendation PA166297135",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059737,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297038",
            "name": "Recommendation PA166297038",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059640,
                "html": "<p>Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297122",
            "name": "Recommendation PA166297122",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059724,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297025",
            "name": "Recommendation PA166297025",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059627,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297157",
            "name": "Recommendation PA166297157",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059759,
                "html": "<p>Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297012",
            "name": "Recommendation PA166297012",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059614,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297117",
            "name": "Recommendation PA166297117",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059719,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297104",
            "name": "Recommendation PA166297104",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059706,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297051",
            "name": "Recommendation PA166297051",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059653,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297099",
            "name": "Recommendation PA166297099",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059701,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297007",
            "name": "Recommendation PA166297007",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059609,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297086",
            "name": "Recommendation PA166297086",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059688,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297183",
            "name": "Recommendation PA166297183",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059785,
                "html": "<p>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.0",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297139",
            "name": "Recommendation PA166297139",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059741,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166296991",
            "name": "Recommendation PA166296991",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059593,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297126",
            "name": "Recommendation PA166297126",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059728,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297073",
            "name": "Recommendation PA166297073",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059675,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297170",
            "name": "Recommendation PA166297170",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059772,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297029",
            "name": "Recommendation PA166297029",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059631,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297060",
            "name": "Recommendation PA166297060",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059662,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297113",
            "name": "Recommendation PA166297113",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059715,
                "html": "<p>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297016",
            "name": "Recommendation PA166297016",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059618,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297109",
            "name": "Recommendation PA166297109",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059711,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297188",
            "name": "Recommendation PA166297188",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059790,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297043",
            "name": "Recommendation PA166297043",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059645,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297140",
            "name": "Recommendation PA166297140",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059742,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297175",
            "name": "Recommendation PA166297175",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059777,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.5",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297030",
            "name": "Recommendation PA166297030",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059632,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166296995",
            "name": "Recommendation PA166296995",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059597,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297065",
            "name": "Recommendation PA166297065",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059667,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297118",
            "name": "Recommendation PA166297118",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059720,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166301337",
            "name": "Recommendation Annotation PA166301337",
            "population": null,
            "classification": null,
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452095656,
                "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x\u22653</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x\u22653</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x\u22653</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x\u22653</strong> or <strong>*2x2 versus *2x\u22653</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x\u22653</td>\n<td>Increased</td>\n<td>\u22653</td>\n<td></td>\n<td></td>\n<td>\u22653</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
            },
            "implications": [],
            "lookupKey": {
                "CYP2D6": "xN combinations",
                "CYP2C19": "No Result"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297052",
            "name": "Recommendation PA166297052",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059654,
                "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297105",
            "name": "Recommendation PA166297105",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059707,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166296986",
            "name": "Recommendation PA166296986",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059588,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297091",
            "name": "Recommendation PA166297091",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059693,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297144",
            "name": "Recommendation PA166297144",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059746,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297047",
            "name": "Recommendation PA166297047",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059649,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166296999",
            "name": "Recommendation PA166296999",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059601,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297131",
            "name": "Recommendation PA166297131",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059733,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297179",
            "name": "Recommendation PA166297179",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059781,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.5",
                "CYP2C19": "No Result"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297034",
            "name": "Recommendation PA166297034",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059636,
                "html": "<p>Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297166",
            "name": "Recommendation PA166297166",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059768,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297021",
            "name": "Recommendation PA166297021",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059623,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297069",
            "name": "Recommendation PA166297069",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059671,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166301333",
            "name": "Recommendation Annotation PA166301333",
            "population": null,
            "classification": null,
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452095652,
                "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x\u22653</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x\u22653</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x\u22653</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x\u22653</strong> or <strong>*2x2 versus *2x\u22653</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x\u22653</td>\n<td>Increased</td>\n<td>\u22653</td>\n<td></td>\n<td></td>\n<td>\u22653</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
            },
            "implications": [],
            "lookupKey": {
                "CYP2D6": "xN combinations",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297153",
            "name": "Recommendation PA166297153",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059755,
                "html": "<p>Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297056",
            "name": "Recommendation PA166297056",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059658,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297136",
            "name": "Recommendation PA166297136",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059738,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297083",
            "name": "Recommendation PA166297083",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059685,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297180",
            "name": "Recommendation PA166297180",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059782,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.0",
                "CYP2C19": "No Result"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297039",
            "name": "Recommendation PA166297039",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059641,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297070",
            "name": "Recommendation PA166297070",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059672,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297123",
            "name": "Recommendation PA166297123",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059725,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297026",
            "name": "Recommendation PA166297026",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059628,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297110",
            "name": "Recommendation PA166297110",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059712,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297158",
            "name": "Recommendation PA166297158",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059760,
                "html": "<p>Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297013",
            "name": "Recommendation PA166297013",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059615,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166301341",
            "name": "Recommendation Annotation PA166301341",
            "population": null,
            "classification": null,
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452095660,
                "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x\u22653</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x\u22653</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x\u22653</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x\u22653</strong> or <strong>*2x2 versus *2x\u22653</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x\u22653</td>\n<td>Increased</td>\n<td>\u22653</td>\n<td></td>\n<td></td>\n<td>\u22653</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
            },
            "implications": [],
            "lookupKey": {
                "CYP2D6": "xN combinations",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297092",
            "name": "Recommendation PA166297092",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059694,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297145",
            "name": "Recommendation PA166297145",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059747,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297000",
            "name": "Recommendation PA166297000",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059602,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297048",
            "name": "Recommendation PA166297048",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059650,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297008",
            "name": "Recommendation PA166297008",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059610,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297087",
            "name": "Recommendation PA166297087",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059689,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297184",
            "name": "Recommendation PA166297184",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059786,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.5",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166296990",
            "name": "Recommendation PA166296990",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059592,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297074",
            "name": "Recommendation PA166297074",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059676,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297127",
            "name": "Recommendation PA166297127",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059729,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297171",
            "name": "Recommendation PA166297171",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059773,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297061",
            "name": "Recommendation PA166297061",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059663,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297017",
            "name": "Recommendation PA166297017",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059619,
                "html": "<p>Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297101",
            "name": "Recommendation PA166297101",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059703,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297096",
            "name": "Recommendation PA166297096",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059698,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297149",
            "name": "Recommendation PA166297149",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059751,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297004",
            "name": "Recommendation PA166297004",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059606,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297193",
            "name": "Recommendation PA166297193",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059795,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297176",
            "name": "Recommendation PA166297176",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059778,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.75",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297031",
            "name": "Recommendation PA166297031",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059633,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297079",
            "name": "Recommendation PA166297079",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059681,
                "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166296994",
            "name": "Recommendation PA166296994",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059596,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297066",
            "name": "Recommendation PA166297066",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059668,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297163",
            "name": "Recommendation PA166297163",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059765,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297119",
            "name": "Recommendation PA166297119",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059721,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297053",
            "name": "Recommendation PA166297053",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059655,
                "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297150",
            "name": "Recommendation PA166297150",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059752,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297009",
            "name": "Recommendation PA166297009",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059611,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166296985",
            "name": "Recommendation PA166296985",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059587,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297106",
            "name": "Recommendation PA166297106",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059708,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297088",
            "name": "Recommendation PA166297088",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059690,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297185",
            "name": "Recommendation PA166297185",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059787,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "3.0",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166296998",
            "name": "Recommendation PA166296998",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059600,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166301336",
            "name": "Recommendation Annotation PA166301336",
            "population": null,
            "classification": null,
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452095655,
                "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x\u22653</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x\u22653</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x\u22653</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x\u22653</strong> or <strong>*2x2 versus *2x\u22653</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x\u22653</td>\n<td>Increased</td>\n<td>\u22653</td>\n<td></td>\n<td></td>\n<td>\u22653</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
            },
            "implications": [],
            "lookupKey": {
                "CYP2D6": "xN combinations",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297132",
            "name": "Recommendation PA166297132",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059734,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297035",
            "name": "Recommendation PA166297035",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059637,
                "html": "<p>Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297167",
            "name": "Recommendation PA166297167",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059769,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297022",
            "name": "Recommendation PA166297022",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059624,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297154",
            "name": "Recommendation PA166297154",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059756,
                "html": "<p>Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297057",
            "name": "Recommendation PA166297057",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059659,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166296989",
            "name": "Recommendation PA166296989",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059591,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297189",
            "name": "Recommendation PA166297189",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059791,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297044",
            "name": "Recommendation PA166297044",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059646,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297071",
            "name": "Recommendation PA166297071",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059673,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297124",
            "name": "Recommendation PA166297124",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059726,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297027",
            "name": "Recommendation PA166297027",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059629,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297111",
            "name": "Recommendation PA166297111",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059713,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297159",
            "name": "Recommendation PA166297159",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059761,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297014",
            "name": "Recommendation PA166297014",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059616,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297093",
            "name": "Recommendation PA166297093",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059695,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297146",
            "name": "Recommendation PA166297146",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059748,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297001",
            "name": "Recommendation PA166297001",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059603,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297190",
            "name": "Recommendation PA166297190",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059792,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297049",
            "name": "Recommendation PA166297049",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059651,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297080",
            "name": "Recommendation PA166297080",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059682,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297036",
            "name": "Recommendation PA166297036",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059638,
                "html": "<p>Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166301340",
            "name": "Recommendation Annotation PA166301340",
            "population": null,
            "classification": null,
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452095659,
                "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x\u22653</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x\u22653</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x\u22653</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x\u22653</strong> or <strong>*2x2 versus *2x\u22653</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x\u22653</td>\n<td>Increased</td>\n<td>\u22653</td>\n<td></td>\n<td></td>\n<td>\u22653</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
            },
            "implications": [],
            "lookupKey": {
                "CYP2D6": "xN combinations",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297075",
            "name": "Recommendation PA166297075",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059677,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297172",
            "name": "Recommendation PA166297172",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059774,
                "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297128",
            "name": "Recommendation PA166297128",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059730,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297115",
            "name": "Recommendation PA166297115",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059717,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297062",
            "name": "Recommendation PA166297062",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059664,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297018",
            "name": "Recommendation PA166297018",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059620,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297097",
            "name": "Recommendation PA166297097",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059699,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297102",
            "name": "Recommendation PA166297102",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059704,
                "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297005",
            "name": "Recommendation PA166297005",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059607,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297194",
            "name": "Recommendation PA166297194",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059796,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297084",
            "name": "Recommendation PA166297084",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059686,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.25",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297137",
            "name": "Recommendation PA166297137",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059739,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.75",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297181",
            "name": "Recommendation PA166297181",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059783,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.25",
                "CYP2C19": "No Result"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297164",
            "name": "Recommendation PA166297164",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059766,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166296993",
            "name": "Recommendation PA166296993",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059595,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297067",
            "name": "Recommendation PA166297067",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059669,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166301339",
            "name": "Recommendation Annotation PA166301339",
            "population": null,
            "classification": null,
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452095658,
                "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x\u22653</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x\u22653</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x\u22653</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x\u22653</strong> or <strong>*2x2 versus *2x\u22653</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x\u22653</td>\n<td>Increased</td>\n<td>\u22653</td>\n<td></td>\n<td></td>\n<td>\u22653</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
            },
            "implications": [],
            "lookupKey": {
                "CYP2D6": "xN combinations",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297054",
            "name": "Recommendation PA166297054",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059656,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.25",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297151",
            "name": "Recommendation PA166297151",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059753,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297107",
            "name": "Recommendation PA166297107",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059709,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297186",
            "name": "Recommendation PA166297186",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059788,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.75",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297041",
            "name": "Recommendation PA166297041",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059643,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297089",
            "name": "Recommendation PA166297089",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059691,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166296997",
            "name": "Recommendation PA166296997",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059599,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166296984",
            "name": "Recommendation PA166296984",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059586,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297076",
            "name": "Recommendation PA166297076",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059678,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297173",
            "name": "Recommendation PA166297173",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059775,
                "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297120",
            "name": "Recommendation PA166297120",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059722,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297168",
            "name": "Recommendation PA166297168",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059770,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297023",
            "name": "Recommendation PA166297023",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059625,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166301335",
            "name": "Recommendation Annotation PA166301335",
            "population": null,
            "classification": null,
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452095654,
                "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x\u22653</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x\u22653</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x\u22653</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x\u22653</strong> or <strong>*2x2 versus *2x\u22653</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x\u22653</td>\n<td>Increased</td>\n<td>\u22653</td>\n<td></td>\n<td></td>\n<td>\u22653</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
            },
            "implications": [],
            "lookupKey": {
                "CYP2D6": "xN combinations",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297010",
            "name": "Recommendation PA166297010",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059612,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297058",
            "name": "Recommendation PA166297058",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059660,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166296988",
            "name": "Recommendation PA166296988",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059590,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297142",
            "name": "Recommendation PA166297142",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059744,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297045",
            "name": "Recommendation PA166297045",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059647,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297177",
            "name": "Recommendation PA166297177",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059779,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "1.0",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297032",
            "name": "Recommendation PA166297032",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059634,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297112",
            "name": "Recommendation PA166297112",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059714,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297015",
            "name": "Recommendation PA166297015",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059617,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297147",
            "name": "Recommendation PA166297147",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059749,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "n/a",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297094",
            "name": "Recommendation PA166297094",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059696,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297191",
            "name": "Recommendation PA166297191",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059793,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "No Result"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297002",
            "name": "Recommendation PA166297002",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059604,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297081",
            "name": "Recommendation PA166297081",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059683,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.5",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297134",
            "name": "Recommendation PA166297134",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059736,
                "html": "<p>Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297037",
            "name": "Recommendation PA166297037",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059639,
                "html": "<p>Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "2.25",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297121",
            "name": "Recommendation PA166297121",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059723,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297169",
            "name": "Recommendation PA166297169",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059771,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.75",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297024",
            "name": "Recommendation PA166297024",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059626,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297129",
            "name": "Recommendation PA166297129",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059731,
                "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "1.0",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297063",
            "name": "Recommendation PA166297063",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059665,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297116",
            "name": "Recommendation PA166297116",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059718,
                "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0",
                "CYP2C19": "Indeterminate"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297160",
            "name": "Recommendation PA166297160",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059762,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "2.5",
                "CYP2C19": "Likely Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297019",
            "name": "Recommendation PA166297019",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059621,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "3.0",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297103",
            "name": "Recommendation PA166297103",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059705,
                "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297050",
            "name": "Recommendation PA166297050",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059652,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0",
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297098",
            "name": "Recommendation PA166297098",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059700,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297006",
            "name": "Recommendation PA166297006",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059608,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297085",
            "name": "Recommendation PA166297085",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059687,
                "html": "<p>Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.5",
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297138",
            "name": "Recommendation PA166297138",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059740,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "4.0",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297182",
            "name": "Recommendation PA166297182",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059784,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.75",
                "CYP2C19": "No Result"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166296992",
            "name": "Recommendation PA166296992",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059594,
                "html": "<p>Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
            ],
            "lookupKey": {
                "CYP2D6": "0.0",
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297125",
            "name": "Recommendation PA166297125",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059727,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
                "CYP2D6: Normal metabolism of TCAs"
            ],
            "lookupKey": {
                "CYP2D6": "1.75",
                "CYP2C19": "Likely Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297072",
            "name": "Recommendation PA166297072",
            "population": "general",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059674,
                "html": "<p>Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
            },
            "implications": [
                "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
                "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5",
                "CYP2C19": "Rapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297028",
            "name": "Recommendation PA166297028",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059630,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
            },
            "implications": [
                "CYP2C19: Normal metabolism of tertiary amines",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "No Result",
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297195",
            "name": "Recommendation PA166297195",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA448385",
                    "name": "amitriptyline",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452059797,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "CYP2C19: n/a",
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "n/a",
                "CYP2C19": "No Result"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        }
    ],
    "citations": [
        {
            "pmid": "27997040",
            "title": "Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.",
            "authors": [
                "Hicks J K",
                "Sangkuhl K",
                "Swen J J",
                "Ellingrod V L",
                "M\u00fcller D J",
                "Shimoda K",
                "Bishop J R",
                "Kharasch E D",
                "Skaar T C",
                "Gaedigk A",
                "Dunnenberger H M",
                "Klein T E",
                "Caudle K E",
                "Stingl J C"
            ],
            "journal": "Clinical pharmacology and therapeutics",
            "year": 2017
        },
        {
            "pmid": "23486447",
            "title": "Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.",
            "authors": [
                "Hicks J K",
                "Swen J J",
                "Thorn C F",
                "Sangkuhl K",
                "Kharasch E D",
                "Ellingrod V L",
                "Skaar T C",
                "M\u00fcller D J",
                "Gaedigk A",
                "Stingl J C",
                "Clinical Pharmacogenetics Implementation Consortium"
            ],
            "journal": "Clinical pharmacology and therapeutics",
            "year": 2013
        }
    ],
    "version": "2024-03-25-16-13"
}